Paclitaxel-Coated Balloon Matches Rapamycin-Eluting Stent in De Novo Small-Vessel Coronary Disease
核心洞察
A prospective randomized controlled trial reports non-inferiority of a paclitaxel-coated balloon (搜索) versus a rapamycin-eluting metal stent (搜索) for de novo, non-complex small coronary vessel disease (搜索).
The trial addresses a lesion subset where drug-coated balloons are increasingly positioned as an alternative to permanent metallic scaffolds in percutaneous coronary intervention.
Drug-coated balloons deliver antiproliferative drug locally without leaving a permanent implant, potentially avoiding late thrombosis, neoatherosclerosis and prolonged dual antiplatelet therapy.
A prospective, randomized controlled trial has demonstrated non-inferiority of a paclitaxel-coated balloon (搜索) compared with a rapamycin-eluting metal stent (搜索) in patients with de novo, non-complex small coronary vessel disease (搜索), according to the trial report. The head-to-head comparison places drug-coated balloon (DCB) technology directly against a contemporary drug-eluting stent (DES) platform in a lesion subset that remains a focus of interventional cardiology research.
Rationale for a "Leave Nothing Behind" Strategy
DCB technology has become an increasingly transformative option in percutaneous coronary intervention. By locally delivering antiproliferative drugs without leaving a permanent scaffold, DCBs address several limitations associated with drug-eluting stents, including late thrombosis, neoatherosclerosis, impaired vasomotion, and the long duration of dual antiplatelet therapy. This "leave nothing behind" concept aligns with current trends in interventional cardiology, focusing on vascular healing and long-term safety.
Expanding evidence has positioned DCBs as a credible alternative to DES across a wide range of coronary pathologies. Although DCBs are well established for in-stent restenosis (搜索), their application in more complex coronary subsets — such as de novo disease, bifurcations, diffuse and long lesions, and small vessel disease — continues to evolve.
Where the Evidence Base Stands
The randomized comparison of a paclitaxel-coated balloon (搜索) with a rapamycin-eluting metal stent (搜索) adds to a growing body of literature on DCB use in de novo coronary lesions. Advances in coating technology, imaging techniques, and lesion preparation methods have significantly improved procedural outcomes, yet important gaps remain. Current practice still varies across centers, and long-term registry data are needed to confirm sustained benefit and clarify patient and lesion characteristics that predict success.
Understanding the mechanistic basis for DCB performance and integrating standardized procedural strategies remain priorities in the field. Key open questions include drug transfer kinetics, excipients, coating durability, and vessel wall interactions across DCB platforms, as well as the role of lesion preparation strategies such as scoring and cutting balloons, atherectomy, and intravascular lithotripsy in optimizing DCB outcomes.
Unresolved Questions in Complex Lesions
Beyond small-vessel and de novo disease, investigators continue to examine DCB-only and hybrid approaches for bifurcation and main vessel disease, including procedural algorithms intended to minimize restenosis, and management strategies for diffuse and long lesions that avoid extensive metallic scaffolding and preserve future surgical options.
Imaging-guided intervention using intravascular ultrasound and optical coherence tomography for procedural planning and post-intervention evaluation is another area of active investigation, alongside mid- and long-term endpoints such as target lesion failure, vessel remodeling, and clinical outcomes beyond 12 months. Predictors of failure — including geographic miss, flow-limiting dissection, and the need for bailout stenting — remain targets for procedural refinement.
Real-world and all-comer data are also needed, particularly from patients with diabetes, chronic kidney disease, or high bleeding risk, populations in which avoiding a permanent implant and shortening antiplatelet therapy may hold particular appeal. Cost-effectiveness and resource use, together with further advances in pharmacology and coating materials, will shape how DCB strategies are positioned against contemporary DES in daily practice.